Merck & Co Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hi, I am Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Merck.
Despite the impact COVID-19 has had on the industry, the underlying revenue growth for Merck's key products underscore that its oncology, vaccines, animal health and select hospital specialty care products as well as margin expansion opportunities remain underappreciated. Therefore, multiple expansion should drive Merck's shares higher as customer access gets better despite the ongoing pandemic and earnings visibility improves beyond the KEYTRUDA patent cliff in 2028.
Therefore, we're very excited to have with us Merck's Chief Marketing Officer, Mike Nally, today to discuss the future direction of the company.
Questions & Answers
Mike, it's not too early anymore to start thinking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
